UroGen Pharma (NASDAQ: [[ticker:URGN]]) has appointed Liz Barrett to serve as its president and CEO. Barrett is also joining the board of directors of the company, which was founded in Israel and recently moved its headquarters to New York. UroGen, a clinical-stage company developing treatments for urologic cancers, says Barrett will be based in New York.
Barrett comes to UroGen from Novartis (NYSE: [[ticker:NVS]]), where she was CEO of Novartis Oncology. Her experience also includes posts at Pfizer (NYSE: [[ticker:PFE]]), Cephalon, and Johnson & Johnson (NYSE: [[ticker:JNJ]]). Barrett succeeds Ron Bentsur, who had been CEO of UroGen since 2015. UroGen says Bentsur will advise the company to ease Barrett’s transition. UroGen is in the process of filing for FDA approval of UGN-101, the company’s experimental treatment for low-grade upper tract urothelial cancer.
